Dr. Mauro addresses the debate over selecting first line therapy with three approved agents available.
Michael J. Mauro, MDVideo Categories: CML
Two-pronged attack on chemotherapy-resistant leukemia cells
An Early Look at Research From the 2016 ASCO Annual Meeting
Drug against breast cancer is also highly potent against a frequent form of leukaemia
Improving natural killer cancer therapy: Study
Website Design by Inverse Paradox